Clinical meaning
Disseminated intravascular coagulation (DIC) is a life-threatening acquired syndrome characterized by the paradoxical simultaneous activation of widespread intravascular coagulation and secondary fibrinolysis, resulting in microvascular thrombosis causing end-organ ischemia alongside consumption of clotting factors and platelets producing hemorrhage. DIC is never a primary diagnosis but always occurs secondary to an underlying trigger condition, most commonly sepsis (35-40% of cases), malignancy (particularly acute promyelocytic leukemia, pancreatic adenocarcinoma, and mucin-secreting tumors), obstetric catastrophes (placental abruption, amniotic fluid embolism, retained dead fetus, pre-eclampsia/HELLP syndrome), massive trauma with tissue destruction, and severe hemolytic transfusion reactions. Understanding the dual pathophysiology of clotting and bleeding occurring simultaneously is essential for nurses managing these critically ill patients. The coagulation cascade is normally maintained in a tightly regulated equilibrium between procoagulant factors, natural anticoagulant mechanisms (antithrombin III, protein C/protein S system, tissue factor pathway inhibitor), and the fibrinolytic system. In DIC, this balance is catastrophically disrupted through three interconnected pathophysiological mechanisms. The first mechanism is massive, uncontrolled activation of the tissue factor (TF) pathway. In sepsis, bacterial endotoxins (lipopolysaccharide from gram-negative organisms) and inflammatory cytokines (tumor necrosis factor-alpha, interleukin-1, interleukin-6) stimulate monocytes, macrophages, and damaged endothelial cells to express tissue factor on their surfaces. In trauma, crushed tissues release tissue factor directly into the circulation. In obstetric emergencies, placental tissue and amniotic fluid are rich sources of tissue factor. Tissue factor binds Factor VII, forming the TF-VIIa complex that activates Factor X and initiates the common pathway of coagulation, generating thrombin. The second mechanism involves thrombin generation becoming massive and uncontrolled. The enormous quantities of thrombin produced overwhelm the natural anticoagulant defenses. Antithrombin III (AT-III) is consumed faster than it can be produced, its levels dropping to critically low values. Thrombin activates protein C, but the protein C-thrombomodulin system becomes saturated and ineffective. The endothelial glycocalyx, which normally provides anticoagulant heparan sulfate proteoglycans, is damaged by inflammatory mediators, further reducing antithrombin activity. With these natural brakes failing, thrombin converts massive amounts of fibrinogen to fibrin, which deposits as microthrombi throughout the microvasculature of virtually every organ. These microthrombi obstruct capillaries and small vessels, causing ischemia and infarction in end-organs including the kidneys (acute cortical necrosis), lungs (ARDS), liver (hepatic failure), brain (altered mental status, stroke), skin (purpura fulminans, digital gangrene), and adrenal glands (Waterhouse-Friderichsen syndrome in meningococcal sepsis). The third mechanism is the secondary activation of the fibrinolytic system. As fibrin is deposited throughout the vasculature, tissue plasminogen activator (tPA) is released from damaged endothelium and converts plasminogen to plasmin. Plasmin degrades the fibrin clots, producing fibrin degradation products (FDPs) and D-dimers (specific cross-linked fibrin fragments). These FDPs themselves have anticoagulant properties: they inhibit fibrin polymerization (preventing effective clot formation), impair platelet aggregation, and interfere with thrombin activity. The result is a devastating positive feedback loop: clotting produces fibrin, fibrinolysis destroys it and releases anticoagulant FDPs, which prevent effective hemostasis while clotting continues to consume factors. The consumption of clotting factors (fibrinogen, Factor V, Factor VIII, Factor XIII) and platelets by the ongoing microvascular coagulation depletes the hemostatic reserve, producing the characteristic bleeding diathesis. Patients bleed from venipuncture sites, surgical wounds, mucosal surfaces, and body orifices because they lack sufficient platelets and clotting factors to form effective hemostatic plugs. DIC can present in two clinical forms. Acute (overt, decompensated) DIC presents dramatically with simultaneous bleeding and thrombosis, most commonly seen in sepsis, major trauma, and obstetric emergencies. The International Society on Thrombosis and Haemostasis (ISTH) DIC scoring system quantifies the degree of coagulopathy using platelet count, D-dimer/FDP elevation, prolonged prothrombin time (PT), and fibrinogen level, with a score of 5 or greater indicating overt DIC. Chronic (non-overt, compensated) DIC develops insidiously, often in malignancy, where the bone marrow and liver can partially compensate for factor consumption, and may present primarily with thrombotic complications (deep vein thrombosis, pulmonary embolism, arterial thrombosis) rather than hemorrhage. Trousseau syndrome (migratory superficial thrombophlebitis) in cancer patients is a classic manifestation of chronic DIC.